Crowdonomics
Ron Artesano

Reg CF · Convertible Note · Feb 2023

ClosedReached targetReg CFConvertible Note
via WeFunderView campaign
Raised
$130.5K / $350K max
37% of ceiling · target hit day 5
Investors
122
$1.1K avg
Valuation cap
$3M
cap, not an agreed valuation

Raised over time

Cumulative raisedInvestors
$130K$65K$0
122610
Feb 15, 2023 · openedMay 1, 2023 · last reading
Target ($50K) hit — Feb 20, 2023, day 5Deadline Apr 30, 2023

Left axis: cumulative dollars raised. Right axis: cumulative investors. Live figures via WeFunder; investor counts may lag the platform by up to a day.

Financials disclosed in this offering

FY2020–FY2021 · hover for source
$0
FY2020
$49K
−$94K
FY2021
RevenueNet income
Metric
FY2020 reviewed
FY2021 reviewed
Income statement
Revenue
$0
$49,301
Cost of goods sold
$0
$27,189
Gross margin
—
45%
Net income
$0
-$93,796
Taxes paid
$0
$0
Balance sheet
Cash
$97,696
$20,404
Accounts receivable
$0
$49,301
Total assets
$105,335
$133,338
Short-term debt
$0
$4,819
Long-term debt
$0
$0
Total liabilities
$0
$4,819
Other
Headcount
—
3

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

1 amendment
  1. Mar 6, 2023
    Terms not yet extracted from this filing
    Form C/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. The quoted reason is the issuer’s own statement from the Form C/A.

Deal terms

Valuation cap$3M
Interest rate9%

Offering details

Target$50,000
Max$350,000
Min investment$250
OpenedFeb 15, 2023
DeadlineApr 30, 2023
ClosedMay 1, 2023
Days active75

Links & provenance

Source: Manual
0001670254-23-000094

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.